Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasmActive, not recruitingPhase 32024-12-17NCT04027309

3 results · Page 1 of 1

193 results · Page 1 of 8

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
AT-Graz-MEDUNIGRAZGrazAustria2
AT-Innsbruck-IMEDInnsbruckAustria2
AT-Linz-KEPLERLinzAustria2
AT-Linz-ORDENSKLINIKUMLinzAustria3
AT-Salzburg-SALKSalzburgAustria3
AT-Vienna-HANUSCHViennaAustria4
AU-Adelaide-FLINDERSAdelaideAustralia3
AU-Adelaide-RAHAdelaideAustralia4
AU-Brisbane-PAHBrisbaneAustralia3
AU-Brisbane-RBWHBrisbaneAustralia3
AU-Camperdown-RPACamperdownAustralia3
AU-Douglas-TOWNSVILLEDouglasAustralia3
AU-Geelong VIC-BARWONHEALTHGeelongAustralia1
AU-Gosford NSW-GOSFORDHOSPITALGosfordAustralia1
AU-Hobart TAS-RHOBARTHobartAustralia2
AU-Melbourne-ALFREDMelbourneAustralia4
AU-Melbourne-AUSTINMelbourneAustralia3
AU-Melbourne-BOXHILLMelbourneAustralia1
AU-Melbourne-MONASHMelbourneAustralia5
AU-Melbourne-RMELBOURNEMelbourneAustralia2
AU-Melbourne-SVHMMelbourneAustralia3
AU-Perth-FSHPerthAustralia3
AU-Perth-RPHPerthAustralia2
AU-Perth-SCGHPerthAustralia3
AU-Sydney-CONCORDSydneyAustralia2